fruquintinib + sintilimab + SOX

DRUG2 trials

Sponsors

Henan Cancer Hospital, Sichuan University

Conditions

Esophagogastric Junction AdenocarcinomaGastric AdenocarcinomaGastric Cancer

Phase 2

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Active, not recruitingNCT05177068

Henan Cancer HospitalGastric Cancer

Start: 2022-05-13End: 2025-12-31Target: 42Updated: 2025-10-02

Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma

Not yet recruitingNCT07658872

Sichuan UniversityEsophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma

Start: 2026-06-15End: 2028-04-06Target: 120Updated: 2026-06-22

Related Papers

Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated response and surgical results from a single-arm, phase 2 clinical trial.

Journal of Clinical Oncology2025-05-28

PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial.

Journal of Clinical Oncology2025-01-271 citations

Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.

Journal of Clinical Oncology2024-06-011 citations